SPRED1 Mutations in a Neurofibromatosis Clinic

• Published in: Journal of child neurology 2010-10, Vol.25 (10), p.1203-1209
• Main Authors: Muram-Zborovski, Talia M, Stevenson, David A, Viskochil, David H, Dries, David C, Wilson, Andrew R, Mao, Rong
• Format: Article
• Language: English
• ISSN: 0883-0738; 1708-8283
• DOI: 10.1177/0883073809359540

Legius syndrome, caused by SPRED1 mutations, has phenotypic overlap with neurofibromatosis type 1 (NF1) without tumorigenic manifestations. Patients fulfilling the NIH diagnostic criteria for NF1 were enrolled from the University of Utah NF Clinic and SPRED1 mutation analysis performed in order to identify the frequency of Legius syndrome within an NF1 clinic population. SPRED1 sequencing was performed on 151 individuals with the clinical diagnosis of NF1 and 2 individuals (1.3%) were found to have novel SPRED1 mutations, p.R18X and p.Q194X. The phenotypes for the two individuals with SPRED1 mutations included altered pigmentation without tumorigenesis. A specific SPRED1 haplotype allele was identified in 27 individuals. The frequency of SPRED1 mutations in patients meeting diagnostic criteria for NF1 in a hospital-based clinic is 1–2%. The likelihood an individual is harboring a SPRED1 mutation increases with age if multiple, non-pigmentary NF1 findings are absent. Legius syndrome patients may benefit from altered medical surveillance.